Work Here?
Overview
Pathos combines artificial intelligence with oncology to speed up cancer drug development. It analyzes large oncology datasets, including genomics, using advanced AI and machine learning to identify novel therapeutic targets and biomarkers, guiding the creation of more effective, personalized cancer treatments. The company collaborates with pharmaceutical and biotechnology partners to de-risk pipelines, shorten development timelines, and increase the odds of success for new cancer therapies. Pathos differentiates itself by offering an integrated data-driven platform that leverages diverse genomic and clinical data to drive target validation and biomarker discovery for partner programs. Its goal is to accelerate the delivery of better cancer treatments by turning complex data into actionable insights.
About Pathos
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series D
Total Funding
$365M
Headquarters
Chicago, Illinois
Founded
2022
Simplify's Take
What believers are saying
- $365M Series D funding in 2026 values Pathos at $1.6B to expand AI oncology platform.
- AstraZeneca $200M partnership with Tempus validates PathOS for multimodal oncology model development.
- Q1 2026 acquisition of DeuterOncology stake creates portfolio returns beyond licensing fees.
What critics are saying
- Pathios Therapeutics' PTT-4256 GPR65 inhibitor captures immunotherapy market share within 12-24 months.
- AstraZeneca diverts resources to Tempus-led model, sidelining PathOS within 6-12 months.
- Pocenbrodib trial underperforms versus abiraterone/olaparib by Q2 2026, exhausting cash reserves.
What makes Pathos unique
- Pathos AI's PathOS platform integrates multiomic data for biomarker-driven patient selection in mCRPC trials.
- Foundry platform identified DO-2 MET inhibitor with 100% tumor shrinkage and 5% edema in Phase 1 NSCLC.
- Pocenbrodib targets novel CBP/p300 proteins to overcome resistance in post-anti-androgen mCRPC patients.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$365M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Benefits
Hybrid Work Options
Remote Work Options
401(k) Retirement Plan
401(k) Company Match
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 4%2 year growth
↑ 4%Pathos AI has raised $365m in a Series D funding round as it prepares to widen its AI-enabled platform to advance the development of oncology drugs.
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion.
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) - Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member.
Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery.
Pathos is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Pathos
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series D
Total Funding
$365M
Headquarters
Chicago, Illinois
Founded
2022
Pathos is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today